Zimmer Biomet is carefully growing its global reach to meet the significant demand in the musculoskeletal field.
Zimmer Biomet Holdings, Inc. is showcasing its wide range of orthopedic and musculoskeletal products at the AAOS 2025 Annual Meeting in San Diego from March 10-14. The company has recently launched new technologies for knee and upper extremity reconstruction, including the newly approved Persona® Revision SoluTion™ Femur. Additionally, they are introducing ZBX™ Ambulatory Surgery Center Solutions.
Zimmer Biomet Holdings, Inc., a leading company in medical technology, announced on March 7, 2025, that it has received FDA 510(k) clearance for its Persona® Revision SoluTion™ Femur. This new revision knee implant component provides an option for patients who are sensitive to specific metals.
WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a leading company in medical technology worldwide, has announced that Kristen Cardillo has been named Senior Vice President and Chief Communications Officer.
Zimmer Biomet is facing challenges because of economic uncertainties, pressure on prices, and negative changes in currency exchange rates.
Zimmer Biomet's shares are priced at $105, reflecting a value of 13 times their adjusted earnings, as the company keeps expanding despite challenges from a GLP-1 drug. Although the benefits of the 2015 merger are still being realized, recent growth and mergers and acquisitions show potential, with sales expected to grow in the mid-single digits. The $1.2 billion acquisition of Paragon 28 improves their foot and ankle orthopedic offerings, even if it temporarily lowers earnings per share.
Zimmer Biomet gains advantages from its varied range of products beyond just orthopedics, as well as its smart investments in promising, fast-growing areas.
While the revenue and earnings per share (EPS) for Zimmer (ZBH) provide insight into its performance for the quarter ending December 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.
Zimmer Biomet (ZBH) reported quarterly earnings of $2.31 per share, which is higher than the Zacks Consensus Estimate of $2.30 per share. This is an increase compared to earnings of $2.20 per share from the same period last year.
In the fourth quarter, net sales reached $2.023 billion, showing a 4.3% increase, or 4.9% when adjusted for constant currency. The diluted earnings per share for the quarter were $1.20, while the adjusted figure was $2.31. For the entire year, net sales totaled $7.679 billion, up by 3.8% or 4.8% on a constant currency basis, with diluted earnings per share at $4.43 and adjusted earnings at $8.00.